June 07, 2021
SUZHOU, China, June 7, 2021 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) is presented in a poster session at the ASCO 2021 (2021 American Society of Clinical Oncology Annual Meeting).
Esophageal cancer is one of the most common malignant tumors in the world. According to data released by GLOBOCAN 2020, approximately 320,000 new cases occurred in China in 2020, accounting for half of the global new cases, of which esophageal squamous cell carcinoma (ESCC) is the main subtype (90%-95%). The prognosis of esophageal cancer is very poor, with only about 20% overall 5-year survival rate and 3.5% 5-year survival rate for metastatic patients. There is a huge unmet clinical need. KN046-204 is a phase II clinical study
A new study published in the British Journal of Clinical Pharmacology ¬provides insights on how common hospitalized patients develop liver injury from taking different medications.
New insights on how hospitalized patients develop liver injury from taking different drugs
A new study published in the
British Journal of Clinical Pharmacology provides insights on how common hospitalized patients develop liver injury from taking different medications.
When investigators analyzed the records of 156,570 hospitalized patients, they found 499 cases of drug-induced liver injury (DILI), for an incidence of 0.32%. Anti-infective agents, cancer medications, and nonsteroidal anti-inflammatory drugs were the major categories of drugs causing DILI, and the highest incidence was due to voriconazole (an antifungal medication). Patients with high cholesterol, cardiovascular disease, pre-existing liver disease, and prior surgeries faced a higher risk of DILI.
A new study published in the British Journal of Clinical Pharmacology provides insights on how common hospitalized patients develop liver injury from.